Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesType I Gonadotropin-Releasing Hormone Receptor (GnRH-R) Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells
Journal of Clinical Endocrinology and Metabolism, 02/12/09
Marelli MM et al. - GnRH-II exerts a specific and significant antiproliferative action on prostate cancer cells. This antitumor effect is mediated by the activation of type I (but not of type II) GnRH-R and by its coupled cAMP intracellular signaling pathway.
Today in Endocrine...keeping you current
Receive free subspecialty "5-minute updates" via email
A new FSHbeta mutation in a 29 year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH
European Journal of Endocrinology, 12/18/09
Lower urinary tract symptoms, obesity and the metabolic syndrome
Current Opinion in Urology, 12/09/09
Kisspeptin/GPR54 system as potential target for endocrine disruption of reproductive development and function
International Journal of Andrology, 11/13/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/18/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Article Search
Sponsor